Valuation: Jazz Pharmaceuticals plc

Market Cap 15.96B 13.83B 12.97B 11.82B 22.25B 1,523B 22.6B 153B 59.61B 762B 59.92B 58.62B 2,543B P/E 2026 *
17.4x
P/E 2027 * 15.5x
Enterprise Value 17.38B 15.07B 14.13B 12.88B 24.23B 1,659B 24.62B 166B 64.93B 831B 65.26B 63.85B 2,771B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.15x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-1.24%
1 week-4.21%
Current month-2.77%
1 month+3.75%
3 months+5.82%
6 months+47.83%
Current year+44.62%
1 week 243.74
Extreme 243.74
261.28
1 month 233.46
Extreme 233.4601
265.04
Current year 156.95
Extreme 156.95
265.04
1 year 116.53
Extreme 116.53
265.04
3 years 95.49
Extreme 95.49
265.04
5 years 95.49
Extreme 95.49
265.04
10 years 86.88
Extreme 86.88
265.04
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
Change 5-day change 1-year change 3-year change Capi.($)
-1.24%-4.21%+109.91%+76.43% 15.96B
-0.92%+1.43%+83.05%+128.86% 1,078B
+0.47%+1.98%+50.26%+50.75% 632B
+0.83%+2.85%+24.49%+64.82% 443B
-1.68%-2.83%+42.70%+34.76% 356B
-1.36%-3.00%+23.97%+34.40% 289B
-1.67%-3.10%-0.51%+3.71% 245B
+0.40%+3.21%+44.42%+59.17% 226B
+0.46%-1.61%-7.49%-51.53% 204B
+1.67%+5.56%+14.98%+72.68% 171B
Average -0.60%+0.87%+38.58%+47.40% 365.97B
Weighted average by Cap. -0.55%+1.28%+45.62%+65.43%

Financials

2026 *2027 *
Net sales 4.71B 4.08B 3.83B 3.49B 6.57B 450B 6.67B 45.07B 17.59B 225B 17.68B 17.3B 751B 4.97B 4.31B 4.04B 3.69B 6.93B 475B 7.05B 47.59B 18.58B 238B 18.67B 18.27B 793B
Net income 975M 845M 792M 722M 1.36B 93.02B 1.38B 9.32B 3.64B 46.56B 3.66B 3.58B 155B 1.12B 973M 912M 832M 1.57B 107B 1.59B 10.74B 4.19B 53.63B 4.21B 4.12B 179B
Net Debt 1.42B 1.24B 1.16B 1.06B 1.99B 136B 2.02B 13.63B 5.32B 68.07B 5.35B 5.23B 227B -303M -263M -247M -225M -423M -28.95B -430M -2.9B -1.13B -14.49B -1.14B -1.11B -48.35B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-08-13 US$245.85 -1.24% 468,026
26-08-12 US$248.95 +0.39% 553,511
26-08-11 US$247.98 -3.33% 1,288,298
26-08-10 US$256.52 -0.02% 896,552
26-08-07 US$256.56 -0.04% 970,711
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
245.85USD
Average target price
281.35USD
Spread / Average Target
+14.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock